IMNN

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2007, for Celsion Corporation (Note: The input metadata listed "Imunon, Inc.", but the filing text explicitly identifies the registrant as Celsion Corporation). Celsion is a biotechnology company focused on developing oncology drugs and heat-activated drug delivery systems, specifically its lead candidate ThermoDox. The reporting period is defined by the sale of its former commercial product line, Prolieve, to Boston Scientific Corporation on June 21, 2007, which is now classified as discontinued operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Discontinued Operations: The most significant change is the sale of Prolieve assets to Boston Scientific for $60 million, resulting in a one-time gain of approximately $48 million recorded in the nine-month period. This transformed a net loss of $6.5 million in the prior year's nine-month period into a net income of $38.2 million.
• Operating Expenses: Continuing operations expenses increased significantly. Research and Development (R&D) expenses rose 26% in the quarter and 31% year-to-date, driven by clinical trial costs for ThermoDox (liver and breast cancer studies). General and Administrative (G&A) expenses increased 108% in the quarter and 53% year-to-date, largely due to severance payments, professional fees, and board expenses.
• Balance Sheet: Total assets increased from $18.9 million to $44.8 million, primarily due to $30 million in receivables from Boston Scientific related to the asset sale. Conversely, inventory and trade receivables decreased as the Prolieve business was divested.
• Debt: The company repaid a $15 million loan from Boston Scientific using proceeds from the asset sale. However, a new note payable of approximately $1.1 million was incurred for insurance premiums related to the sale indemnity.

Guidance, Outlook, and Risks

• Outlook: Management expects to expend approximately $3.1 million for the remainder of fiscal year 2007 on clinical testing and overhead, funded by current cash resources. The company anticipates future revenue from licensing fees and royalties rather than direct product sales.
• Subsequent Events: On November 9, 2007, Celsion entered into a $6.5 million credit facility with Manufacturers and Traders Trust Company (M&T). Advances are limited to $1.5 million per month and are contingent on the company maintaining cash balances below $500,000 (excluding collateral).
• Risks and Contingencies:
  • Indemnification: Celsion agreed to indemnify Boston Scientific for up to $15 million regarding unforeseen intellectual property claims related to Prolieve. A reserve of $3.7 million was recorded as of September 30, 2007.
  • Liquidity: The company has a history of negative cash flows from operations and relies on equity sales or asset sales for funding. The new credit facility is secured by substantially all company assets.
  • Regulatory: Future success depends on FDA approval for ThermoDox, which is currently in Phase I/II clinical trials.

Investor Verification Checklist

• Receivables from Boston Scientific: Verify the collectability of the $30 million receivable due from the Prolieve asset sale, noting the payment schedule (installments over two years).
• Indemnification Reserve: Review the $3.7 million liability recorded for the $15 million indemnity guarantee to Boston Scientific and the adequacy of the insurance coverage purchased.
• Cash Burn Rate: Assess the sustainability of the $3.1 million projected spend for the remainder of 2007 against the current cash and short-term investment balance of ~$11.3 million.
• ThermoDox Progress: Monitor the status of Phase I/II clinical trials for liver and breast cancer, as this is the primary driver for future valuation.
• Executive Turnover: Note the resignation of the CFO (Anthony Deasey) in September 2007 and the appointment of an Interim Chief Accounting Officer.